Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation

A. Hurrell; A. Beardmore-Gray; K. Duhig; L. Webster; L. C. Chappell; A. H. Shennan

doi:10.1111/1471-0528.16425

Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation

A. Hurrell, A. Beardmore-Gray, K. Duhig, L. Webster, L. C. Chappell, A. H. Shennan^*

^*Corresponding author for this work

Women & Children's Health

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. Tweetable abstract: Placental growth factor in pre-eclampsia: evidence and implementation of testing.

Original language	English
Pages (from-to)	1590-1597
Number of pages	8
Journal	BJOG: An International Journal of Obstetrics and Gynaecology
Volume	127
Issue number	13
DOIs	https://doi.org/10.1111/1471-0528.16425
Publication status	Published - Dec 2020

Keywords

Angiogenic biomarkers
placental growth factor
pre-eclampsia
soluble fms-like tyrosine kinase 1

Access to Document

10.1111/1471-0528.16425

Cite this

@article{eb14719c885d47a3810db6e8a4d76f5c,

title = "Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation",

abstract = "Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. Tweetable abstract: Placental growth factor in pre-eclampsia: evidence and implementation of testing.",

keywords = "Angiogenic biomarkers, placental growth factor, pre-eclampsia, soluble fms-like tyrosine kinase 1",

author = "A. Hurrell and A. Beardmore-Gray and K. Duhig and L. Webster and Chappell, {L. C.} and Shennan, {A. H.}",

year = "2020",

month = dec,

doi = "10.1111/1471-0528.16425",

language = "English",

volume = "127",

pages = "1590--1597",

journal = "BJOG: An International Journal of Obstetrics and Gynaecology",

issn = "1470-0328",

publisher = "Blackwell Publishing Ltd",

number = "13",

}

TY - JOUR

T1 - Placental growth factor in suspected preterm pre-eclampsia

T2 - a review of the evidence and practicalities of implementation

AU - Hurrell, A.

AU - Beardmore-Gray, A.

AU - Duhig, K.

AU - Webster, L.

AU - Chappell, L. C.

AU - Shennan, A. H.

PY - 2020/12

Y1 - 2020/12

N2 - Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. Tweetable abstract: Placental growth factor in pre-eclampsia: evidence and implementation of testing.

AB - Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. Tweetable abstract: Placental growth factor in pre-eclampsia: evidence and implementation of testing.

KW - Angiogenic biomarkers

KW - placental growth factor

KW - pre-eclampsia

KW - soluble fms-like tyrosine kinase 1

UR - http://www.scopus.com/inward/record.url?scp=85089823892&partnerID=8YFLogxK

U2 - 10.1111/1471-0528.16425

DO - 10.1111/1471-0528.16425

M3 - Article

C2 - 32701207

AN - SCOPUS:85089823892

SN - 1470-0328

VL - 127

SP - 1590

EP - 1597

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

IS - 13

ER -

Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this